-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 26, local time, IQVIA released the 2021 Global Oncology Trends Report, which showed that 30 new oncology drugs were approved this year, compared with 104 in the past five year.
IQVIA released its 2021 Global Oncology Trends Report, which showed that 30 new oncology drugs were approved globally this year, while a total of 104 new anti-cancer drugs were launched globally in 2021, a record high in the past five yea.
Global spending on oncology drugs also reaches new highs
Of the 30 new oncology drugs launched, 22 are from the.
Bristol-Myers Squibb's new multiple myeloma drug, Abecma, is the first anti-B cell maturation antigen (anti-BCMA)-directed chimeric antigen receptor (CAR) T cell therapy;
Amgen's new drug for adult non-small cell lung cancer, Lumakras, is the first anticancer therapy targeting specific KRAS gene mutations, marking a new breakthrough in KRAS gene mutation research in the past 40 years;
Novartis' new drug for chronic myeloid leukemia, Scemblix, is the world's first and only approved new STAMP inhibitor, and is the follow-up drug for Gleevec in the treatment of chronic myeloid leukemia;
Additionally, 14 of the 22 drugs received preliminary approval under the FDA's accelerated approval pathw.
In terms of research and development capabilities , according to IQVIA statistics, China has ranked second in the number of new anti-cancer drugs on the market in the past five years, surpassing the sum of the five European countries of France, Germany, Italy, Spain and the United Kingd.
R&D capability China ranks second in the number of new anti-cancer drugs on the market
In terms of research and development , since the first PD-1 inhibitor was approved in 2014, PD-(L)1 has developed into the largest tumor tra.
R & D field
In terms of R&D spending , PD-1/L1 is not the only driver of increased spending on cancer drugs, and the market is increasing R&D investment in new anti-cancer dru.
R & D spending
Going forward, IQVIA expects that with the initial launch of biosimilars and widely available therapies such as Roche's Big Three Herceptin, Rituxan and Avastin The impact wanes, and annual spending growth in the.
Reference source:
Reference source:IBristol's Abecma, Amgen's Lumakras headline record-setting oncology launch class as costs continue to balloon: IQVIA
IBristol's Abecma, Amgen's Lumakras headline record-setting oncology launch class as costs continue to balloon: IQVIA
